Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN) provided a business update and reported Q2 2024 financial results. Key highlights include:

- Advancing Phase 1 trials for XMT-1660 and XMT-2056
- Expecting initial XMT-1660 clinical data and expansion initiation in H2 2024
- $162.7 million cash position as of June 30, 2024
- Capital resources expected to support operations into 2026
- Q2 2024 net loss of $24.3 million ($0.20 per share)
- Collaboration revenue of $2.3 million
- R&D expenses decreased to $17.2 million
- G&A expenses reduced to $10.5 million
- Earned $8 million milestone from Johnson & Johnson collaboration

The company continues to progress its ADC pipeline and collaborations while benefiting from reduced operating expenses.

Positive

• Phase 1 trials for XMT-1660 and XMT-2056 advancing
• Initial XMT-1660 clinical data expected in H2 2024
• Strong cash position of $162.7 million
• Capital resources expected to support operations into 2026
• Earned $8 million milestone from Johnson & Johnson collaboration
• Reduced R&D expenses from $49.0 million to $17.2 million year-over-year
• Decreased G&A expenses from $18.2 million to $10.5 million year-over-year

Negative

• Net loss of $24.3 million in Q2 2024
• Collaboration revenue decreased from $10.7 million to $2.3 million year-over-year

Insights

Financial Analyst

Mersana Therapeutics' Q2 2024 results reveal a mixed financial picture. The company's cash position of $162.7 million is expected to support operations into 2026, providing a solid runway. However, collaboration revenue decreased significantly from $10.7 million in Q2 2023 to $2.3 million in Q2 2024. This decline is concerning but partially offset by reduced expenses.

R&D expenses saw a substantial reduction from $49.0 million to $17.2 million, while G&A expenses decreased from $18.2 million to $10.5 million. These reductions, primarily due to the discontinuation of UpRi and restructuring efforts, have positively impacted the bottom line. Net loss improved from $54.3 million ($0.47 per share) to $24.3 million ($0.20 per share).

The $8 million milestone payment from Johnson & Johnson is a positive development, but investors should monitor future collaboration revenues closely as they've shown volatility.

Oncology Research Analyst

Mersana's pipeline progress is encouraging, with two key ADC candidates advancing in Phase 1 trials. XMT-1660, targeting B7-H4, has reached a dose level of 80 mg/m² every four weeks without hitting maximum tolerated dose. This suggests potential for further dose escalation and optimization. The planned data release and expansion phase initiation in H2 2024 will be important for assessing XMT-1660's potential.

XMT-2056, targeting a novel HER2 epitope, continues enrollment in its dose escalation phase. The recent Nature Communications publication on the Immunosynthen platform adds scientific credibility to this approach. GSK's exclusive global license option for XMT-2056 provides potential for future value realization.

The company's focus on ADCs targeting cancers with high unmet needs positions it well in the competitive oncology landscape. However, concrete efficacy data will be essential for differentiating these candidates from other ADCs in development.

• Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056

• Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024

• Capital resources expected to support current operating plan commitments into 2026

• Conference call today at 8:00 a.m. ET

CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2024.

“The second quarter of 2024 was a time of continued progress at Mersana as we advanced dose escalation in Phase 1 clinical trials of XMT-1660, our lead Dolasynthen ADC candidate, and XMT-2056, our lead Immunosynthen ADC candidate,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics. “At the same time, we made further progress in our collaborations while also benefiting from last year’s efforts to reduce operating expenses. We believe these collective accomplishments have put us in a strong position as we approach our initial clinical data readout for XMT-1660, which is planned for the second half of this year.”

Recent Accomplishments, Strategic Priorities and Expected Milestones

XMT-1660: Mersana continues to advance its Phase 1 clinical trial of XMT-1660, the company’s lead Dolasynthen ADC candidate targeting B7-H4. The dose escalation portion of the trial is ongoing at a dose level of 80 milligrams per meter squared every four weeks, and a maximum tolerated dose has yet to be established. Additionally, the company has been proactively exploring more frequent dosing and enrolling patients in backfill cohorts to inform the optimal dose and schedule for expansion. Mersana plans to share initial safety, tolerability, efficacy and biomarker data from dose escalation and backfill cohorts and plans to initiate the expansion portion of the trial in the second half of 2024.

XMT-2056: Mersana continues to enroll patients in the dose escalation portion of its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen ADC candidate targeting a novel HER2 epitope. GSK plc has an exclusive global license option to co-develop and commercialize XMT-2056. Additionally, mechanistic underpinnings related to Mersana’s Immunosynthen platform were recently described in a Nature Communications publication entitled, “Tumor Cell-Directed STING Agonist Antibody Drug Conjugates Induce Type III Interferons and Anti-Tumor Innate Immune Responses.”

Collaborations: Mersana continues to advance its Johnson & Johnson and Merck KGaA, Darmstadt, Germany collaborations. The collaboration with Merck KGaA, Darmstadt, Germany focuses on the discovery of novel Immunosynthen ADCs for up to two targets. The collaboration with Johnson & Johnson focuses on the discovery of novel Dolasynthen ADCs for up to three targets. In August 2024, Mersana earned an $8 million development milestone under the Johnson & Johnson collaboration, for which payment is due in the third quarter of 2024.

Second Quarter 2024 Financial Results

• Cash, cash equivalents and marketable securities as of June 30, 2024 were $162.7 million. Mersana continues to expect that its capital resources will be sufficient to support its current operating plan commitments into 2026.
• Net cash used in operating activities for the second quarter of 2024 was $21.8 million.

• Collaboration revenue for the second quarter of 2024 was $2.3 million, compared to $10.7 million for the same period in 2023. The year-over-year change was primarily related to reduced collaboration revenue recognized under Mersana’s collaboration and license agreements with Johnson & Johnson and Merck KGaA, Darmstadt, Germany.
• Research and development (R&D) expenses for the second quarter of 2024 were $17.2 million, compared to $49.0 million for the same period in 2023. Included in R&D expenses for the second quarter of 2024 were $2.4 million in non-cash stock-based compensation expenses. The year-over-year decline in R&D expenses was primarily related to reduced costs associated with manufacturing and clinical activities for UpRi, a discontinued ADC candidate, and reduced employee compensation expense following the company’s restructuring in 2023.
• General and administrative (G&A) expenses for the second quarter of 2024 were $10.5 million, compared to $18.2 million during the same period in 2023. Included in G&A expenses for the second quarter of 2024 were $2.0 million in non-cash stock-based compensation expenses. The year-over-year decline in G&A expenses was primarily related to reduced consulting and professional services fees and reduced employee compensation expense following the aforementioned restructuring.
• Net loss for the second quarter of 2024 was $24.3 million, or $0.20 per share, compared to a net loss of $54.3 million, or $0.47 per share, for the same period in 2023.

Conference Call Reminder
Mersana will host a conference call today at 8:00 a.m. ET to discuss business updates and its financial results for the second quarter of 2024. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Forward-Looking Statements
This press release contains “forward-looking” statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning Mersana’s plans regarding the clinical development of XMT-1660 and XMT-2056, including with respect to the progress and design of the clinical trials of these product candidates; Mersana’s planned data presentations, including with respect to its Phase 1 clinical trial of XMT-1660; Mersana’s cash runway; Mersana’s collaborations with third parties; and the development and potential of Mersana’s product candidates, platforms, technology and pipeline of ADC candidates. Mersana may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including, among other things, uncertainties inherent in research and development, in the advancement, progression and completion of clinical trials and in the clinical development of Mersana’s product candidates, including XMT-1660 and XMT-2056; the risk that Mersana may face delays in patient enrollment in its Phase 1 clinical trial of XMT-2056; the risk that Mersana may not realize the intended benefits of its platforms, technology and collaborations; and other important factors, any of which could cause Mersana’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the section entitled “Risk Factors” in Mersana’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on May 9, 2024, as well as in other filings Mersana may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mersana expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Mersana Therapeutics, Inc. Selected Condensed Consolidated Balance Sheet Data (in thousands and unaudited)
	June 30, 2024				December 31, 2023
Cash, cash equivalents and marketable securities	$	162,742			$	209,084
Working capital(1)	106,779					150,420
Total assets	179,128					226,060
Total stockholders' equity	8,427					36,904
(1)The company defines working capital as current assets less current liabilities.

Mersana Therapeutics, Inc. Condensed Consolidated Statement of Operations (in thousands, except share and per share data, and unaudited)
	Three months ended								Six months ended
	June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
Collaboration revenue	$	2,293			$	10,654			$	11,538			$	18,456
Operating expenses:
Research and development	17,245				48,968				35,931				96,243
General and administrative	10,503				18,187				22,063				36,515
Total operating expenses	27,748				67,155				57,994				132,758
Total other income, net	1,187				2,194				2,882				3,832
Net loss	$	(24,268	)		$	(54,307	)		$	(43,574	)		$	(110,470	)
Net loss per share — basic and diluted	$	(0.20	)		$	(0.47	)		$	(0.36	)		$	(0.99	)
Weighted-average number of common shares — basic and diluted	122,440,124				115,608,156				121,932,540				111,583,765

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

This press release was published by a CLEAR® Verified individual.

FAQ

What are Mersana Therapeutics' (MRSN) key pipeline candidates?

Mersana's key pipeline candidates are XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel HER2 epitope.

When does Mersana (MRSN) expect to announce initial XMT-1660 clinical data?

Mersana expects to announce initial XMT-1660 clinical data in the second half of 2024.

What was Mersana Therapeutics' (MRSN) net loss for Q2 2024?

Mersana reported a net loss of $24.3 million, or $0.20 per share, for Q2 2024.

How much cash does Mersana (MRSN) have as of June 30, 2024?

Mersana reported cash, cash equivalents, and marketable securities of $162.7 million as of June 30, 2024.

What milestone did Mersana (MRSN) earn from its collaboration with Johnson & Johnson?

Mersana earned an $8 million development milestone under the Johnson & Johnson collaboration in August 2024.